Table 2.

RNA binding proteins (RBPs) and known targeting drugs.

RBP	Targeting Drug	Mechanism of Action
IGF2BP1	BTYNB	Allosteric inhibitor of Igf2BP1 in melanoma and ovarial cancer
IGF2BP3	I-BET151	dose-dependent reduction of IGF2BP3 and stagnation of the cells in G1-S phase
MSI2	Ro 08-2750	Competitive inhibition of RNA binding at the RRM1
NCL	Oridonin	Direct inhibitor of NCL
	AS1411	Inactivation of NCL and NFκB leads to hypomethylation and activation of caspase signaling